News headlines about Taro Pharmaceutical Industries (NYSE:TARO) have trended positive this week, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Taro Pharmaceutical Industries earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.1997808039671 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Taro Pharmaceutical Industries (NYSE:TARO) opened at 114.20 on Monday. The firm has a market cap of $4.62 billion, a price-to-earnings ratio of 11.63 and a beta of 0.65. The stock’s 50 day moving average is $106.86 and its 200-day moving average is $111.44. Taro Pharmaceutical Industries has a 12-month low of $92.28 and a 12-month high of $124.52.
A number of research firms have recently issued reports on TARO. BidaskClub upgraded shares of Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. TheStreet upgraded shares of Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a report on Thursday, July 20th.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.